Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
暂无分享,去创建一个
V. Backer | M. Braddock | Dave Singh | C. Brightling | R. Chaudhuri | R. Olivenstein | G. Colice | C. Ulrik | J. FitzGerald | L. Mcgarvey | B. Leaker | T. Harrison | David Cohen | R. Russell | S. Siddiqui | L. Chachi | I. Titlestad | Millie M Wang | H. Parikh | L. H. Nordenmark | Millie Wang | L. Nordenmark | D. Cohen | Michel Laviolette | Richard J. Russell | Timothy Harrison | Rekha Chaudhuri | David Cohen | Tina Skjold | Læge Carl Nielsen | P. Howarth
[1] C. Brightling,et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. , 2018, The Lancet. Respiratory medicine.
[2] C. Brightling,et al. Asthma , 2018, The Lancet.
[3] C. Brightling,et al. New and emerging drug treatments for severe asthma , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[4] Richard Beasley,et al. After asthma: redefining airways diseases , 2017, The Lancet.
[5] J. Corren,et al. Tezepelumab in Adults with Uncontrolled Asthma , 2017, The New England journal of medicine.
[6] E. Bleecker,et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.
[7] W. Busse,et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.
[8] E. Bateman,et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. , 2016, The Lancet. Respiratory medicine.
[9] I. Pavord,et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. , 2016, The Lancet. Respiratory medicine.
[10] E. R. Sutherland,et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.
[11] M. Braddock,et al. Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma. , 2016, American journal of respiratory and critical care medicine.
[12] A. Sousa,et al. Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study , 2016, The Journal of allergy and clinical immunology.
[13] M. Weatherall,et al. Serum periostin in obstructive airways disease , 2016, European Respiratory Journal.
[14] C. Brightling,et al. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease , 2016, Therapeutic advances in chronic disease.
[15] P. O'Byrne,et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. , 2015, The Lancet. Respiratory medicine.
[16] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[17] W. Busse,et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.
[18] Ian D Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.
[19] E. Bleecker,et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.
[20] W. Busse,et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.
[21] C. Brightling,et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.
[22] Ella A. Kazerooni,et al. CT-based Biomarker Provides Unique Signature for Diagnosis of COPD Phenotypes and Disease Progression , 2012, Nature Medicine.
[23] C. Brightling,et al. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry , 2012, Thorax.
[24] Nicola A Hanania,et al. Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.
[25] C. Brightling,et al. Interleukin‐13: prospects for new treatments , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[26] Ana Sousa,et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.
[27] I. Pavord,et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness , 2006, European Respiratory Journal.
[28] R. Puri,et al. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis , 2006, Nature Medicine.
[29] R. Panettieri,et al. IL‐13 enhances agonist‐evoked calcium signals and contractile responses in airway smooth muscle , 2003, British journal of pharmacology.
[30] A. Kay,et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.
[31] J. Kinet,et al. Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. , 2001, American Journal of Respiratory and Critical Care Medicine.
[32] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .